Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2021;32(4):331-7
Article Links
Challenges in Applying Treat to Target Strategy in Sample of Iraqi Patients with Rheumatoid Arthritis
Nizar Abdulateef Jassim1, Asal Adnan Redha2
Authors Information

1. Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq

2. Department of Rheumatology, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq

Keywords: Rheumatoid arthritis, treat to target, disease control, disease activity measure, barriers
References
  1. Zerbini CA, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Una CR, et al. Biologic therapies and bone loss in rheumatoid arthritis. Osteoporosis Int 2017;28(2):429-446.
  2. Van Vugt RM, Rijken PJ, Rietveld AG, Van Vugt VC, Dijkmans BAC. Antioxidant intervention in rheumatoid arthritis: results of an open pilot study. Clin Rheumatol 2008;27(6):771-5.
  3. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69(4):631-7.
  4. Stoffer M, Schoels M, Smolen J, Aletaha D, Breedveld F, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69(4):638-43.
  5. Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl L, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63(3):573-86.
  6. Wabe N, Sorich MJ, Wechalekar MD,Cleland L, McWilliams L, Lee A, et al. Characterising deviation from treat-to- target strategies for early rheumatoid arthritis: the first three years. Arthritis Res Ther
  7. 2015;17(1):48.
  8.  Aletaha D, Neogi T, Silman AJ, Funovits J, Felson D, Bingham C, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-81.
  9. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35:498-502.
  10. Anderson J, Caplan L, Yazdany J, Robbins M, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.
  11. Arthritis Care Res (Hoboken) 2012;64(5):640-7.
  12. de Klerk E, van der Heijde D, Landewé R, Tempel H, Linden S. The compliance-questionnaire- rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003;30(11):2469-75.
  13. Tymms K, Zochling J, Scott J, Bird P, Burnet S, Jager J, et al. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res (Hoboken) 2014;66(2):190-6.
  14. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73(7):1316-22.
  15. Haraoui B, Bensen W, Bessette L, Clercq S, Thorne C, Wade J. Treating rheumatoid arthritis to target: a Canadian physician survey. J Rheumatol 2012;39(5):949-53.
  16. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43(1):22-9.
  17. Forslind K, Hafström I, Ahlmen M, Svensson B. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007;66(1):46-52.
  18. Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez M, Segarra V, Ros S, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 2011;29(6):991.
  19. Jassim NA. Predictors of Response to (Etanercept) in the Treatment of Iraqi Patients with Active Rheumatoid Arthritis. J Fac Med Baghdad 2015;57(1):35-9.
  20. Pers YM, Godfrin-Valnet M, Lambert J, Fortunet C, Constant E, Mura T, et al. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 2015;42:580-4.
  21. Mirpourian M, Salesi M, Abdolahi H, Farajzadegan Z, Karimzadeh H. The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis. J Res Med Sci 2014;19:509-14.